睿知中国医院研究地图
候选清单

杭州

浙江省人民医院

Zhejiang Provincial People's Hospital

在本站收录的 53 种疾病中,这家医院列在其中 19 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

浙江省人民医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma4 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma4 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma119 篇牵头论文
  4. 胃癌Stomach cancer37 篇牵头论文
  5. 视网膜母细胞瘤Retinoblastoma0 篇牵头论文
  6. 骨肉瘤Osteosarcoma4 篇牵头论文
  7. 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
  8. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  9. 尤文肉瘤Ewing sarcoma0 篇牵头论文
  10. 多发性骨髓瘤Multiple myeloma10 篇牵头论文
  11. 重症肌无力Myasthenia gravis2 篇牵头论文
  12. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  13. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
  14. 法布雷病Fabry disease1 篇牵头论文
  15. 杜氏肌营养不良Duchenne muscular dystrophy0 篇牵头论文
  16. 白塞病Behçet disease0 篇牵头论文
  17. IgA 肾病IgA nephropathy4 篇牵头论文
  18. 原发性胆汁性胆管炎Primary biliary cholangitis4 篇牵头论文
  19. 原发性硬化性胆管炎Primary sclerosing cholangitis2 篇牵头论文

未列出的收录疾病:肝母细胞瘤、脊索瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 2220242025: 002025

杭州有 8 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
    分期
    不分期
    开始
    2023-06
    登记号
    NCT05892354

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:广西医科大学第一附属医院;另有 13 家列出的医院为研究中心南宁、南昌、广州、杭州、柳州、桂林、梧州、海口、福州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室耳鼻喉/头颈外科

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.1%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 3320242025: 002025

杭州有 6 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题分子标志物与基因免疫治疗新辅助与综合治疗
论文中的科室放疗科
牵头的论文4
  1. Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis.2024BMC cancer免费全文
  2. Lymph node ratio is a prognostic indicator for locally advanced esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy.2024Biomolecules & biomedicine免费全文
  3. Annexin A2 combined with TTK accelerates esophageal cancer progression via the Akt/mTOR signaling pathway.2024Cell death & disease免费全文
  4. Ubiquitin‑conjugating enzymes as potential biomarkers and therapeutic targets for digestive system cancers (Review).2023Oncology reports免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors状态不明NCT05602792研究中心I/II期2020-04 启动
  2. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
PubMed 以外找到的论文(未计入)12
  1. Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial2025International Journal of Radiation Oncology*Biology*Physics论文
  2. Abstract CT213: Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C2024Cancer Research会议摘要
  3. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C.2024Journal of Clinical Oncology会议摘要
  4. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C.2024Journal of Clinical Oncology会议摘要
  5. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from multi-cohort, multi-center phase II trial ALTER-G-001-cohort A.2024Journal of Clinical Oncology会议摘要
  6. Effect of PLCE1-driven aerobic glycolysis through ENO1 modulation on immune evasion in esophageal squamous cell carcinoma (ESCC).2024Journal of Clinical Oncology会议摘要
  7. 103P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A2023Annals of Oncology论文
  8. 150P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C2023Annals of Oncology论文
  9. 1628P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)2023Annals of Oncology论文
  10. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Results from a multi-cohort, multicenter phase II trial (ALTER-G-001).2023Journal of Clinical Oncology会议摘要
  11. P-104 Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)2023Annals of Oncology会议摘要
  12. Epigenetically inhibiting CYP3A5 modulates the migration and invasion of esophageal squamous cell carcinoma via ZEB22022Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 119 篇,占 0.8%。

牵头论文
119
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 191920212022: 232320222023: 212120232024: 282820242025: 24242025

杭州有 7 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。

这些数字背后的记录
研究主题复发与预后手术与肝移植影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科病理/检验科消化/肝病科影像/核医学科
牵头的论文119
  1. Development and validation of machine learning-based model for predicting early recurrence for patients with HBV-associated hepatocellular carcinoma after curative hepatectomy.2026American journal of surgery
  2. Hepatic stellate cells shape the ECM-disorganized and immunosuppressive microenvironment via CCL11/CCR3 axis in lenvatinib-treated hepatocellular carcinoma.2026Cellular signalling
  3. Development and validation of a personalized web-based calculator of aggressive recurrence after surgery for early-stage hepatocellular carcinoma by machine learning.2026Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  4. A non-invasive decision tree predicting recurrence-free survival after liver transplantation for hepatocellular carcinoma.2026Hepatobiliary & pancreatic diseases international : HBPD INT
  5. Tumor-Targeted PLGA Nanospheres Enhance Therapeutic Effect of Lenvatinib in Hepatocellular Carcinoma via Photothermal and Photodynamic Therapy.2025ACS applied materials & interfaces
  6. Cancer Cell-Derived Exosomal miR-500a-3p Modulates Hepatic Stellate Cell Activation and the Immunosuppressive Microenvironment.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  7. Transcription factor FOXC2 regulates miR-145/ADAMTS5 axis to inhibit angiogenesis in hepatocellular carcinoma via circular RNA 0002898.2025BMC cancer免费全文
  8. Machine learning predicts post-transplant muscle loss in hepatocellular carcinoma patients without sarcopenia.2025BMC cancer免费全文
  9. Epigenetic-modification associated hnRNPA3 acts as a prognostic biomarker and promotes malignant progression of HCC.2025BMC cancer免费全文
  10. Developing a novel predictive model for identifying risk factors associated with being lost to follow-up among high-risk patients for recurrence following radical resection of hepatocellular carcinoma: the first report.2025BMC cancer免费全文
  11. Radiofrequency ablation combined with immunotherapy to treat hepatocellular carcinoma: a comprehensive review.2025BMC surgery免费全文
  12. Noninvasive prediction of Glypican-3 expression in hepatocellular carcinoma using Habitat-based and peritumoral CT radiomics: a nomogram approach.2025Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  13. RSK2-mediated phosphorylation and degradation of UBE2O inhibits hepatocellular carcinoma growth and resistance to radiotherapy.2025Cancer letters
  14. YY1 induced USP13 transcriptional activation drives the malignant progression of hepatocellular carcinoma by deubiquitinating WWP1.2025Cellular & molecular biology letters免费全文
  15. IGF2BP1/AIFM2 axis regulates ferroptosis and glycolysis to drive hepatocellular carcinoma progression.2025Cellular signalling
  16. Targeting Glycolytic Enzymes with 3-Bromopyruvic Acid to Enhance the Efficacy of Interventional Embolization in Hepatocellular Carcinoma.2025Current medical science
  17. Mesenchymal circulating tumor cells as prognostic markers in HCC Post-Transplantation: Sirolimus as a potential therapeutic Modulator.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  18. Outcomes and risk factors for liver transplantation using steatotic grafts for hepatocellular carcinoma: a multicenter study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  19. Dual-Mode Treatment of Hepatocellular Carcinoma Using RGD Cyclopeptide-Modified Liposomes Loaded with Ce6/DOX.2025International journal of nanomedicine免费全文
  20. Parkin modulates the hepatocellular carcinoma microenvironment by regulating PD-1/PD-L1 signalling.2025Journal of advanced research免费全文
  21. Tumor-microenvironment responsive nanomodulator for near infrared photothermal immunotherapy of hepatocellular carcinoma.2025Journal of nanobiotechnology免费全文
  22. Multi-omic analysis reveals a CAF-stemness-governed classification in HCC liver transplant recipients beyond the Milan criteria.2025Nature communications免费全文
  23. Perioperative and long-term outcomes of laparoscopic liver resection for combined hepatocellular carcinoma and cholangiocarcinoma versus intrahepatic cholangiocarcinoma: A propensity score matching analysis.2025PloS one免费全文
  24. The value of prealbumin in predicting post hepatectomy liver failure for patients with hepatocellular carcinoma undergoing major hepatectomy.2025Scientific reports免费全文
  25. Prognostic poteintial of polyamine metabolism-related genes in hepatocellular carcinoma.2025Scientific reports免费全文
  26. Radiomics analysis based on dynamic contrast-enhanced MRI for predicting early recurrence after hepatectomy in hepatocellular carcinoma patients.2025Scientific reports免费全文
  27. Unraveling the Causal Links Between Immune Traits and Hepatocellular Carcinoma: Insights From a Bi-Directional Mendelian Randomization Study.2025The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology免费全文
  28. Prediction of posthepatectomy liver failure in patients with hepatocellular carcinoma through ultrasound elastography.2025World journal of gastroenterology免费全文
  29. Peptide Transporter 1-Mediated Dipeptide Transport Promotes Hepatocellular Carcinoma Metastasis by Activating MAP4K4/G3BP2 Signaling Axis.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  30. Dual effects of targeting neuropilin-1 in lenvatinib-resistant hepatocellular carcinoma: inhibition of tumor growth and angiogenesis.2024American journal of physiology. Cell physiology
  31. Development and validation of prealbumin-bilirubin score (preALBI score) for predicting long-term survival after hepatectomy for hepatocellular carcinoma: A multicenter analysis versus ALBI score.2024American journal of surgery
  32. The Prognostic Value of Preoperative Serum Markers and Risk Classification in Patients with Hepatocellular Carcinoma.2024Annals of surgical oncology
  33. Survival benefit from adjuvant TACE combined with lenvatinib for patients with hepatocellular carcinoma and microvascular invasion after curative hepatectomy.2024Asian journal of surgery
  34. Establishment of a novel ferroptosis-correlative lncRNA signature and validation of ST3GAL4-AS1 for predicting overall survival of hepatocellular carcinoma.2024Asian journal of surgery
  35. Survival benefit of adjuvant TACE for patients with hepatocellular carcinoma and child-pugh B7 or B8 after hepatectomy.2024BMC cancer免费全文
  36. Chitinase-3 like-protein-1, a prognostic biomarker in patients with hepatocellular carcinoma and concomitant myosteatosis.2024BMC cancer免费全文
  37. Comparison of percutaneous microwave/radiofrequency ablation liver partition and portal vein embolization versus transarterial chemoembolization and portal vein embolization for planned hepatectomy with insufficient future liver remnant.2024BMC cancer免费全文
  38. Identification and validation of palmitoylation metabolism-related signature for liver hepatocellular carcinoma.2024Biochemical and biophysical research communications
  39. FAM188B promotes the growth, metastasis, and invasion of hepatocellular carcinoma by targeting the hnRNPA1/PKM2 axis.2024Biochimica et biophysica acta. Molecular cell research
  40. UCHL3 promotes hepatocellular carcinoma progression by stabilizing EEF1A1 through deubiquitination.2024Biology direct免费全文
  41. OTUD5 promotes the growth of hepatocellular carcinoma by deubiquitinating and stabilizing SLC38A1.2024Biology direct免费全文
  42. USP40 promotes hepatocellular carcinoma cell proliferation, migration and stemness by deubiquitinating and stabilizing Claudin1.2024Biology direct免费全文
  43. Impact of immunosuppressants on tumor pulmonary metastasis: new insight into transplantation for hepatocellular carcinoma.2024Cancer biology & medicine免费全文
  44. Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma.2024Expert opinion on drug metabolism & toxicology
  45. Multicenter propensity score-matched analysis to compare perioperative morbidity after laparoscopic or robotic complex hepatectomy for solitary hepatocellular carcinoma.2024HPB : the official journal of the International Hepato Pancreato Biliary Association
  46. Mild photothermal activation of TRPV1 pathway for enhanced calcium ion overload therapy of hepatocellular carcinoma.2024International journal of biological macromolecules
  47. Unveiling the Role of Mechanical Microenvironment in Hepatocellular Carcinoma: Molecular Mechanisms and Implications for Therapeutic Strategies.2024International journal of biological sciences免费全文
  48. Black Phosphorus Nanosheets-Loaded Single-Atom Gold Nanoenzymes for Enhanced Photodynamic Therapy of Hepatocellular Carcinoma.2024International journal of nanomedicine免费全文
  49. Letter to Editor: 'Identification of patients with favorable prognosis after resection in intermediate-stage hepatocellular carcinoma'.2024International journal of surgery (London, England)免费全文
  50. Myosteatosis and muscle loss impact liver transplant outcomes in male patients with hepatocellular carcinoma.2024Journal of cachexia, sarcopenia and muscle免费全文
  51. LYRM2 Promotes the Growth and Metastasis of Hepatocellular Carcinoma via Enhancing HIF-1α-Dependent Glucose Metabolic Reprogramming.2024Journal of cellular and molecular medicine免费全文
  52. Letter to the editor: 'A simple scoring system to predict early recurrence after surgical resection for hepatocellular carcinoma'.2024Liver international : official journal of the International Association for the Study of the Liver
  53. Transcription factor 7 like 2 promotes metastasis in hepatocellular carcinoma via NEDD9-mediated activation of AKT/mTOR signaling pathway.2024Molecular medicine (Cambridge, Mass.)免费全文
  54. Inhibiting the compensatory elevation of xCT collaborates with disulfiram/copper-induced GSH consumption for cascade ferroptosis and cuproptosis.2024Redox biology免费全文
  55. The p-MYH9/USP22/HIF-1α axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma.2024Signal transduction and targeted therapy免费全文
  56. Letter to the editor: "Risk factors, patterns, and outcome predictors of late recurrence in patients with hepatocellular carcinoma after curative resection: A large cohort study with long-term follow-up results".2024Surgery
  57. Comprehensive analysis of cell death genes in hepatocellular carcinoma based on multi-omics data.2023Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  58. Comparison of diagnostic performance of AFP, DCP and two diagnostic models in hepatocellular carcinoma: a retrospective study.2023Annals of hepatology
  59. Pure laparoscopic resection of a large caudate-lobe mass guided by three-dimensional reconstruction and green fluorescence navigation.2023Asian journal of surgery
  60. Prognostic value of platelet distribution width to lymphocyte ratio in patients with hepatocellular carcinoma following hepatectomy.2023BMC cancer免费全文
  61. MEX3C as a potential target for hepatocellular carcinoma drug and immunity: combined therapy with Lenvatinib.2023BMC cancer免费全文
  62. UBE2K promotes the malignant progression of hepatocellular carcinoma by regulating c-Myc.2023Biochemical and biophysical research communications
  63. Polydopamine-Modified Zeolite Imidazole Framework Drug Delivery System for Photothermal Chemotherapy of Hepatocellular Carcinoma.2023Biomacromolecules
  64. Upregulation of MED7 was associated with progression in hepatocellular carcinoma.2023Cancer biomarkers : section A of Disease markers免费全文
  65. The prognosis of elderly patients with hepatocellular carcinoma after curative hepatectomy a multicenter competing risk analysis.2023Clinics and research in hepatology and gastroenterology
  66. Exosomal miR-374c-5p derived from mesenchymal stem cells suppresses epithelial-mesenchymal transition of hepatocellular carcinoma via the LIMK1-Wnt/β-catenin axis.2023Environmental toxicology
  67. Survival benefit of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after anatomical hepatectomy.2023Expert review of gastroenterology & hepatology
  68. Metabolic rearrangements and intratumoral heterogeneity for immune response in hepatocellular carcinoma.2023Frontiers in immunology免费全文
  69. Transcatheter arterial chemoembolization after percutaneous microwave ablation and portal vein embolization for advanced hepatocellular carcinoma.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  70. Association of severity in the grading of microvascular invasion with long-term oncological prognosis after liver resection for early-stage hepatocellular carcinoma: a multicenter retrospective cohort study from a hepatitis B virus-endemic 2023International journal of surgery (London, England)免费全文
  71. Five machine learning-based radiomics models for preoperative prediction of histological grade in hepatocellular carcinoma.2023Journal of cancer research and clinical oncology免费全文
  72. Rab11-FIP4 interacts with ARF5 to promote cancer stemness in hepatocellular carcinoma.2023Journal of physiology and biochemistry
  73. Hypoxia-induced UBE2K promotes the malignant progression of HCC.2023Pathology, research and practice
  74. LncRNA FRMD6-AS1 promotes hepatocellular carcinoma cell migration and stemness by regulating SENP1/HIF-1α axis.2023Pathology, research and practice
  75. A novel metabolism-related gene signature in patients with hepatocellular carcinoma.2023PeerJ免费全文
  76. Short- and long-term outcomes of laparoscopic versus open liver resection for large hepatocellular carcinoma: a propensity score study.2023Surgery today
  77. Preoperative prediction of macrotrabecular-massive hepatocellular carcinoma through dynamic contrast-enhanced magnetic resonance imaging-based radiomics.2023World journal of gastroenterology免费全文
  78. Editorial: non-viral hepatocellular carcinoma surveillance-an increasingly severe public health issue.2022Alimentary pharmacology & therapeutics
  79. Letter: sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma.2022Alimentary pharmacology & therapeutics
  80. Diagnostic accuracy of circulating microRNAs for hepatitis C virus-associated hepatocellular carcinoma: a systematic review and meta-analysis.2022BMC infectious diseases免费全文
  81. Actinidia chinensis Planch Root extract suppresses the growth and metastasis of hypopharyngeal carcinoma by inhibiting E2F Transcription Factor 1-mediated MNX1 antisense RNA 1.2022Bioengineered免费全文
  82. Graphene quantum dots mediated magnetic chitosan drug delivery nanosystems for targeting synergistic photothermal-chemotherapy of hepatocellular carcinoma.2022Cancer biology & therapy免费全文
  83. High expression of PPM1G is associated with the progression and poor prognosis of hepatocellular carcinoma.2022Cancer biomarkers : section A of Disease markers免费全文
  84. Resistance of Lenvatinib in Hepatocellular Carcinoma.2022Current cancer drug targets
  85. Letter to editor: Does age effect on the short- and long-term outcomes of patients undergoing liver resection for hepatocellular carcinoma?2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  86. Impact of diabetes mellitus on the long-term prognosis of patients with hepatocellular carcinoma after hepatectomy.2022Expert review of gastroenterology & hepatology
  87. Low expression of moonlight gene ALAD is correlated with poor prognosis in hepatocellular carcinoma.2022Gene
  88. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty live2022Hepatobiliary & pancreatic diseases international : HBPD INT
  89. LncRNA ALKBH3-AS1 enhances ALKBH3 mRNA stability to promote hepatocellular carcinoma cell proliferation and invasion.2022Journal of cellular and molecular medicine免费全文
  90. Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma.2022Journal of hepatology
  91. HBsAg seroclearance and reduction in late recurrence of HBV-related HCC: Causality or co-existence?2022Journal of hepatology
  92. Methodological considerations regarding a gene signature to predict microvascular invasion in hepatocellular carcinoma.2022Journal of hepatology
  93. Preoperative prediction of microvascular invasion: Is invasive biopsy of HCC necessary?2022Journal of hepatology
  94. The association of microvascular invasion with satellite nodule, tumor multiplicity, tumor encapsulation and resection margin of hepatocellular carcinoma.2022Journal of hepatology
  95. The updated BCLC staging system needs further refinement: A surgeon's perspective.2022Journal of hepatology
  96. The correlation of fibrinogen-like protein-1 expression with the progression and prognosis of hepatocellular carcinoma.2022Molecular biology reports免费全文
  97. PHF21A expression as a biomarker of hepatocellular carcinoma progression and prognosis.2022Neoplasma
  98. Konjac glucomannan enhances 5-FU-induced cytotoxicity of hepatocellular carcinoma cells via TLR4/PERK/CHOP signaling to induce endoplasmic reticulum stress.2022Oncology research免费全文
  99. Impact of marital status on overall survival in patients with early-stage hepatocellular carcinoma.2022Scientific reports免费全文
  100. Neoadjuvant immunotherapy for resectable hepatocellular carcinoma.2022The lancet. Gastroenterology & hepatology
  101. An oncolytic adenovirus delivering TSLC1 inhibits Wnt signaling pathway and tumor growth in SMMC-7721 xenograft mice model.2021Acta biochimica et biophysica Sinica
  102. Long-term oncologic outcomes of liver resection for hepatocellular carcinoma in adolescents and young adults: A multicenter study from a hepatitis B virus-endemic area.2021American journal of surgery
  103. Impacts of the SOAT1 genetic variants and protein expression on HBV-related hepatocellular carcinoma.2021BMC cancer免费全文
  104. Identification of Multiple Hub Genes and Pathways in Hepatocellular Carcinoma: A Bioinformatics Analysis.2021BioMed research international免费全文
  105. HIF-1α-activated TM4SF1-AS1 promotes the proliferation, migration, and invasion of hepatocellular carcinoma cells by enhancing TM4SF1 expression.2021Biochemical and biophysical research communications
  106. An Autophagy-Related Gene-Based Prognostic Risk Signature for Hepatocellular Carcinoma: Construction and Validation.2021Computational and mathematical methods in medicine免费全文
  107. Postoperative morbidity adversely impacts long-term oncologic prognosis following hepatectomy for hepatocellular carcinoma: A multicenter observational study.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  108. Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter study.2021Hepatology international
  109. UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway.2021International journal of medical sciences免费全文
  110. Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma.2021Journal of hematology & oncology免费全文
  111. Comment on: Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma.2021Liver international : official journal of the International Association for the Study of the Liver
  112. ZMYND8 promotes the growth and metastasis of hepatocellular carcinoma by promoting HK2-mediated glycolysis.2021Pathology, research and practice
  113. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis.2021Redox biology免费全文
  114. High expression of YKT6 associated with progression and poor prognosis of hepatocellular carcinoma.2021Scandinavian journal of gastroenterology
  115. Biointerfacing Antagonizing T-Cell Inhibitory Nanoparticles Potentiate Hepatocellular Carcinoma Checkpoint Blockade Therapy.2021Small (Weinheim an der Bergstrasse, Germany)
  116. Nanotechnology for Hepatocellular Carcinoma: From Surveillance, Diagnosis to Management.2021Small (Weinheim an der Bergstrasse, Germany)
  117. The Clinical Significance of RMI2 in Hepatocellular Carcinoma.2021Technology in cancer research & treatment免费全文
  118. Low Expression of KAT6B May Affect Prognosis in Hepatocellular Carcinoma.2021Technology in cancer research & treatment免费全文
  119. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study.2021World journal of gastroenterology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)进行中,不再招募NCT05904886研究中心III期2023-09 启动
  2. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC已完成NCT04948697研究中心II期2021-08 启动
  3. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 37 篇,占 0.4%。

牵头论文
37
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 8820212022: 4420222023: 5520232024: 111120242025: 992025

杭州有 9 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    分期
    II期
    开始
    2024-11
    登记号
    NCT06632262

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、厦门、哈尔滨、天津、太原、徐州、成都、杭州、武汉、沈阳、石家庄、襄阳、贵阳、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫与靶向药物腹膜转移与晚期早期发现与内镜
论文中的科室普外/肝胆胰外科消化/肝病科肿瘤内科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文37
  1. Prediction model based on gut microbiota as a non-invasive tool for gastric cancer diagnosis.2025Applied microbiology and biotechnology免费全文
  2. ASPN was higher expression in gastric cancer and associated with poor prognosis through promoting invasion and migration and inducing macrophage M2 polarization.2025BMC cancer免费全文
  3. Histone lactylation drives METTL3 upregulation-mediated RNA m6A modification of CCT2 to hinder CD8+ T cell survival in gastric cancer.2025Cellular and molecular life sciences : CMLS免费全文
  4. Integrated analysis of single-cell and bulk transcriptomes reveals the prognostic value of polyamine metabolism biomarkers and immune microenvironment features in gastric cancer.2025Frontiers in immunology免费全文
  5. NRAV promoted the malignant progression of gastric cancer.2025Gene
  6. FGL1 facilitates rather than suppresses anticancer immunity against microsatellite instable gastric cancer.2025Genes and immunity
  7. PICK1 modulates the proliferation and migration of gastric cancer cells by regulating TLR4.2025Journal of Zhejiang University. Science. B免费全文
  8. The Causal Role of Gut Microbiota and Immune Cell Mediation in Gastroenteropancreatic Neuroendocrine Neoplasms: A Mendelian Randomization Study.2025Neuroendocrinology
  9. Explore the role of CBS in stomach adenocarcinoma based on the sulfur-containing amino acid metabolism network.2025Scientific reports免费全文
  10. 18F-FDG PET/CT metabolism multi-parameter prediction of chemotherapy efficacy in locally progressive gastric cancer.2024Annals of nuclear medicine免费全文
  11. M6A methylation of FKFB3 reduced pyroptosis of gastric cancer by NLRP3.2024Anti-cancer drugs
  12. RARB associated with MSI, affects progression and prognosis of gastric cancer.2024BMC gastroenterology免费全文
  13. A prognostic risk model based on lactate metabolism and transport-related lncRNAs for gastric adenocarcinoma.2024Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  14. WYC-209 inhibited GC malignant progression by down-regulating WNT4 through RARα.2024Cancer biology & therapy免费全文
  15. WYC-209 suppresses gastric cancer by down-regulating FGF18 via inactivating the STAT3 signaling pathway.2024European journal of pharmacology
  16. F2RL3 Regulates Epithelial-Mesenchymal Transition and Angiogenesis in Gastric Cancer through the Rap1/MAPK Signaling Pathway.2024Frontiers in bioscience (Landmark edition)
  17. Weifuchun suppresses the malignancy of gastric cancer cells by targeting KPNA2 through miR-26a-5p-mediated destabilization and the deactivation of the MAPK signaling pathway.2024Journal of ethnopharmacology
  18. Galectin-1 Promotes Gastric Carcinoma Progression and Cisplatin Resistance Through the NRP-1/c-JUN/Wee1 Pathway.2024Journal of gastric cancer免费全文
  19. KIAA1429 promotes gastric cancer progression by destabilizing RASD1 mRNA in an m6A-YTHDF2-dependent manner.2024Journal of translational medicine免费全文
  20. The efficacy and safety of per-nasal "GTS partner" assisted traction technique for gastric endoscopic submucosal dissection: a prospective single-center randomized clinical trial.2024Surgical endoscopyRCT免费全文
  21. Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late-onset cancers.2023Cancer medicine免费全文
  22. KCND2: A prognostic biomarker and regulator of immune function in gastric cancer.2023Cancer medicine免费全文
  23. Helicobacter pylori Infection as a Predictor of Treatment Outcomes of Gastric Cancer: A Systematic Review and Meta-Analysis.2023Digestive diseases (Basel, Switzerland)
  24. Competing endogenous RNA network characterization of lymph node metastases in Leuran gastric cancer subtypes.2023Journal of cancer research and clinical oncology免费全文
  25. Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study.2023World journal of surgical oncology免费全文
  26. Clinicopathological study of gastric schwannoma and review of related literature.2022BMC surgery免费全文
  27. Prognostic role of iodine values for gastric cancer after neoadjuvant chemotherapy: a strong independent prognostic factor.2022Diagnostic and interventional radiology (Ankara, Turkey)免费全文
  28. Identification of three immune subtypes characterized by distinct tumor immune microenvironment and therapeutic response in stomach adenocarcinoma.2022Gene
  29. TLR4 rs4986790 polymorphism confers risk to Helicobacter pylori infection in Zhejiang, China and its enlightenment to nursing care.2022Journal of clinical laboratory analysis免费全文
  30. Research progress on gut microbiota in patients with gastric cancer, esophageal cancer, and small intestine cancer.2021Applied microbiology and biotechnology
  31. Circular RNA circCOL6A3_030 is involved in the metastasis of gastric cancer by encoding polypeptide.2021Bioengineered免费全文
  32. The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review.2021Cancer control : journal of the Moffitt Cancer Center免费全文
  33. Transcription Factor CTCFL Promotes Cell Proliferation, Migration, and Invasion in Gastric Cancer via Activating DPPA2.2021Computational and mathematical methods in medicine免费全文
  34. Protein interacting with C-kinase 1 is involved in epithelial-mesenchymal transformation and suppresses progress of gastric cancer.2021Medical oncology (Northwood, London, England)
  35. Evaluation of the efficiency and safety of combined chemotherapy and molecular-targeted therapy in the treatment of advanced gastric cancer: A protocol for systematic review and meta-analysis.2021Medicine免费全文
  36. RORβ suppresses the stemness of gastric cancer cells by downregulating the activity of the Wnt signaling pathway.2021Oncology reports免费全文
  37. Immunotherapy of gastric cancer: Past, future perspective and challenges.2021Pathology, research and practice
中文论文(未计入)2
  1. [Clinical application of complete laparoscopic gastrectomy with function preservation of cardia in gastric carcinoma].2022Zhonghua yi xue za zhi
  2. [Integrin α5 promotes the proliferation, invasion and adhesion of gastric cancer by regulating the FAK/Src/Rac1 signaling pathway].2021Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer已完成NCT06464965牵头方I期2024-07 启动
  2. A Phase 2 Clinical Study of ABSK061 and ABSK043正在招募NCT06632262研究中心II期2024-11 启动
  3. A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China已完成NCT06585501研究中心2024-08 启动
  4. A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma已终止NCT04718402研究中心I期2021-03 启动
  5. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension已完成NCT04882241研究中心III期2020-07 启动
  6. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  7. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)已完成NCT03675737研究中心III期2018-11 启动
  8. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension已撤回NCT04859582研究中心III期2018-11 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年没有牵头视网膜母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 5 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. miR-140-5p suppresses retinoblastoma cell proliferation, migration, and invasion by targeting CEMIP and CADM3.2018Cellular and molecular biology (Noisy-le-Grand, France)

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 1120242025: 112025

杭州有 22 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 16 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

杭州有 8 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年没有牵头尤文肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

杭州有 6 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
    分期
    I期
    开始
    2025-05
    登记号
    NCT06926283

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心北京、杭州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. [Clinicopathologic and molecular characteristics of malignant gastrointestinal neuroectodermal tumors].2017Zhonghua bing li xue za zhi = Chinese journal of pathology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors正在招募NCT06926283研究中心I期2025-05 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 10 篇,占 0.6%。

牵头论文
10
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 0020232024: 2220242025: 332025

杭州有 9 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层双抗与抗体药物复发与耐药
论文中的科室病理/检验科
牵头的论文10
  1. Reduced ALDH1A1 expression in multiple myeloma cells increases resistance to daratumumab via downregulation of retinoic acid.2025Cellular and molecular life sciences : CMLS免费全文
  2. Performance and comparison of FLCCheck: a novel serum free light chain assay for the Auxiliary Diagnosis of Multiple Myeloma.2025European journal of medical research免费全文
  3. Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database.2025Scientific reports免费全文
  4. Regarding the prognostic role of vitamin D deficiency in a Japanese multiple myeloma study.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  5. Immunoglobulin Replacement Therapy for Hypogammaglobulinemia in Multiple Myeloma Should Not Be Ignored.2024Turkish journal of haematology : official journal of Turkish Society of Haematology免费全文
  6. Defects and countermeasures in laboratory diagnosis of rare IgE multiple myeloma.2022Clinica chimica acta; international journal of clinical chemistry
  7. Role of Tfh17 cells in patients with multiple myeloma.2022Hematology (Amsterdam, Netherlands)
  8. A patient with hypercalcemia and hyperparathyroidism due to adenoma mimicking multiple myeloma.2022International journal of laboratory hematology
  9. Secondary Immunodeficiency and Hypogammaglobulinemia with IgG Levels of <5 g/L in Patients with Multiple Myeloma: A Retrospective Study Between 2012 and 2020 at a University Hospital in China.2021Medical science monitor : international medical journal of experimental and clinical research免费全文
  10. Bone marrow stromal cells derived exosomal miR-10a and miR-16 may be involved in progression of patients with multiple myeloma by regulating EPHA8 or IGF1R/CCND1.2021Medicine免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  2. BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma已完成NCT05376345研究中心I期2022-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

杭州有 6 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。

这些数字背后的记录
研究主题抗体与诊断
论文中的科室风湿免疫科神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

杭州有 9 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

杭州有 11 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

杭州有 7 家医院列在法布雷病下全国有 85 家医院列在法布雷病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。

这些数字背后的记录
牵头的论文1
  1. Status and frontiers of Fabre disease.2025Orphanet journal of rare diseases
早期论文(2016–2020 年)1
  1. Coexistence of Fabry disease with IgM nephropathy: A case report.2019Medicine

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年没有牵头杜氏肌营养不良的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 7 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Population-Wide Duchenne Muscular Dystrophy Carrier Detection by CK and Molecular Testing.2020BioMed research international

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年没有牵头白塞病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 7 家医院列在白塞病下全国有 149 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease已终止NCT04609397研究中心II期2020-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.5%。

牵头论文
4
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 1120242025: 112025

杭州有 15 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科
牵头的论文4
  1. Global glomerulosclerosis proportions predict nephropathy progression in IgA nephropathy: a multicenter retrospective analysis with propensity score matching.2025Renal failure
  2. A patient report scale research to access the symptom burden in patients with IgA nephropathy.2024Scientific reports
  3. Oral Methylprednisolone and Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy.2022JAMA
  4. Mesangial Cell-Derived Exosomal miR-4455 Induces Podocyte Injury in IgA Nephropathy by Targeting ULK2.2022Oxidative medicine and cellular longevity
早期论文(2016–2020 年)2
  1. iTRAQ-based comparative proteomics analysis reveals specific urinary biomarkers for various kidney diseases.2020Biomarkers in medicine
  2. How many podocyte autophagosomes are there in immunoglobulin A nephropathy and idiopathic membranous nephropathy?2016International urology and nephrology
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
  1. MYTP01 for Immune-Mediated Diseases即将招募NCT07901764牵头方不分期2026-12 启动
  2. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases即将招募NCT06774664研究中心I/II期2025-01 启动
  3. A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression进行中,不再招募NCT05797610研究中心III期2023-08 启动
  4. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  5. TESTING -ON Post-Trial ObservatioNal Cohort Study已完成NCT05434325研究中心2022-12 启动
  6. Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy状态不明NCT02231125研究中心IV期2014-09 启动
  7. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)已完成NCT01560052研究中心不分期2012-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.3%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 3320242025: 002025

杭州有 11 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
论文中的科室风湿免疫科普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 2.0%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

杭州有 7 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

浙江省人民医院

Zhejiang Provincial People's Hospital

杭州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Zhejiang Provincial People's Hospital (Affiliated People's Hospital); Zhejiang Provincial People's Hospital (Affiliated People's Hospital; Zhejiang Provincial People's Hospital(Affiliated People's Hospital); Zhejiang Provincial People's Hospital Chun'an Branch; Zhejiang Provincial People's hospital; Zhejiang Provincial People's Hospital Bijie Hospital; Affiliated Zhejiang Provincial People's Hospital; Zhejiang Provincial People' s Hospital

提出更正下载数据